pith. sign in

arxiv: 2606.31085 · v1 · pith:EV5B7ZTOnew · submitted 2026-06-30 · 💻 cs.AI

DDIAgents: Mechanism-Conditioned Context Flow for Drug-Drug Interaction Prediction

Zhenqian Shen , Yu Liu , Xiaoyi Fu , Quanming Yao This is my paper

Pith reviewed 2026-07-01 06:03 UTC · model grok-4.3

classification 💻 cs.AI
keywords drug-drug interaction predictionmulti-agent frameworkmechanism-conditioned reasoningcontext flowinterpretable predictionsknowledge orchestrationbiomedical AI
0
0 comments X

The pith

DDIAgents routes mechanism-specific knowledge to expert agents for more accurate drug-drug interaction predictions.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper introduces a multi-agent framework called DDIAgents that first infers the interaction mechanism between two drugs and then directs relevant evidence only to specialized expert agents matched to that mechanism. A planner agent sets up the experts, supplies each with filtered knowledge sources, and a conclusion agent combines their outputs into a final prediction plus rationale. This setup is meant to cut down on noise from mismatched biomedical data and produce clearer step-by-step reasoning than single-model approaches. If the approach works, it would let AI systems handle the changing relevance of evidence across different interaction types without flooding every step with the full heterogeneous dataset. Readers interested in medication safety would care because better DDI forecasts could reduce adverse events while also making the reasoning traceable to particular agents and mechanisms.

Core claim

DDIAgents is a mechanism-conditioned multi-agent framework that performs DDI prediction through dynamic knowledge orchestration. Given a drug pair, a planner agent instantiates specialized expert agents, routes mechanism-relevant knowledge sources to each agent, and aggregates their analyses through a conclusion agent. By adapting context flow to the inferred interaction mechanism, DDIAgents reduces irrelevant information, supports complementary expert reasoning, and produces interpretable agent-level rationales. Extensive experiments on realistic DDI prediction benchmarks show that DDIAgents consistently outperforms existing feature-based, graph-based, LLM-based, and agent-based baselines.

What carries the argument

mechanism-conditioned context flow in which a planner agent infers the interaction type and routes filtered knowledge to matching expert agents

If this is right

  • Predictions improve because only mechanism-matched evidence reaches each expert instead of the full heterogeneous collection.
  • Each agent's contribution remains traceable, supplying per-agent rationales that explain the final output.
  • The same orchestration pattern can organize other forms of scientific knowledge that vary by underlying mechanism.
  • Performance exceeds that of feature-based, graph-based, LLM-based, and prior agent-based methods on standard DDI benchmarks.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • The same planner-plus-experts structure might transfer to other biomedical tasks where evidence relevance depends on hidden mechanisms, such as adverse event prediction.
  • If the planner's mechanism inference can be audited separately, the system could surface cases where the inferred mechanism itself is uncertain.
  • Replacing the conclusion agent with a voting or evidence-weighing step could further test whether the gain comes mainly from routing or from the aggregation method.

Load-bearing premise

The planner agent can correctly identify which interaction mechanism applies to a given drug pair so that the right experts and knowledge get activated.

What would settle it

A test set of drug pairs whose interaction mechanisms are already labeled by domain experts, where the planner's mechanism inferences match the labels less than 60 percent of the time and performance gains disappear.

Figures

Figures reproduced from arXiv: 2606.31085 by Quanming Yao, Xiaoyi Fu, Yu Liu, Zhenqian Shen.

Figure 1
Figure 1. Figure 1: Three DDI examples with different mechanisms: (a) pharmacokinetic change, (b) pharmacodynamic interference, (c) [PITH_FULL_IMAGE:figures/full_fig_p003_1.png] view at source ↗
Figure 2
Figure 2. Figure 2: The overall framework of the proposed DDIAgents, which iteratively conducts three stages: (a) Expert agent instantia [PITH_FULL_IMAGE:figures/full_fig_p004_2.png] view at source ↗
Figure 3
Figure 3. Figure 3: Comparison between DDIAgents framework and previous multi-agent methods. [PITH_FULL_IMAGE:figures/full_fig_p005_3.png] view at source ↗
Figure 4
Figure 4. Figure 4: A prediction case of DDIAgents. Bold red text indicates incorrect answers and bold green text indicates correct answers. [PITH_FULL_IMAGE:figures/full_fig_p007_4.png] view at source ↗
Figure 6
Figure 6. Figure 6: The performance of DDIAgents and MDAgents with [PITH_FULL_IMAGE:figures/full_fig_p008_6.png] view at source ↗
Figure 5
Figure 5. Figure 5: DDI prediction performance across DDI type fre [PITH_FULL_IMAGE:figures/full_fig_p008_5.png] view at source ↗
Figure 7
Figure 7. Figure 7: Varying the iteration round of DDIAgents. [PITH_FULL_IMAGE:figures/full_fig_p017_7.png] view at source ↗
Figure 8
Figure 8. Figure 8: Knowledge retrieval rates across expert agents and [PITH_FULL_IMAGE:figures/full_fig_p017_8.png] view at source ↗
read the original abstract

Drug-drug interaction (DDI) prediction is essential for medication safety, yet it requires reasoning over heterogeneous biomedical evidence whose relevance changes across interaction mechanisms. We propose DDIAgents, a mechanism-conditioned multi-agent framework that performs DDI prediction through dynamic knowledge orchestration. Given a drug pair, a planner agent instantiates specialized expert agents, routes mechanism-relevant knowledge sources to each agent, and aggregates their analyses through a conclusion agent. By adapting context flow to the inferred interaction mechanism, DDIAgents reduces irrelevant information, supports complementary expert reasoning, and produces interpretable agent-level rationales. Extensive experiments on realistic DDI prediction benchmarks show that DDIAgents consistently outperforms existing feature-based, graph-based, LLM-based, and agent-based baselines. Beyond prediction performance, DDIAgents demonstrates how multi-agent systems can organize heterogeneous scientific knowledge for adaptive and interpretable AI4Science reasoning.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

2 major / 0 minor

Summary. The paper proposes DDIAgents, a mechanism-conditioned multi-agent framework for drug-drug interaction (DDI) prediction. A planner agent infers the interaction mechanism from a drug pair, instantiates specialized expert agents, routes mechanism-relevant knowledge sources to each, and a conclusion agent aggregates their analyses. The central claim is that adapting context flow to the inferred mechanism reduces irrelevant information, enables complementary expert reasoning, produces interpretable rationales, and yields consistent outperformance over feature-based, graph-based, LLM-based, and agent-based baselines on realistic DDI benchmarks.

Significance. If the experimental results and planner inference hold, the framework would illustrate how multi-agent orchestration can adaptively organize heterogeneous biomedical knowledge for DDI prediction, with potential value for interpretable AI4Science applications. The emphasis on mechanism-specific routing and agent-level rationales addresses a relevant challenge in handling varying evidence relevance across interaction types.

major comments (2)
  1. [Abstract] Abstract: the claim of consistent outperformance on realistic benchmarks is asserted without any reported metrics, baselines, controls, or experimental details, preventing assessment of whether results support the central claim that gains arise from mechanism-conditioned flow rather than the multi-agent setup alone.
  2. [Planner agent / mechanism inference (method section)] Planner agent description: the architecture's performance edge requires reliable inference of the interaction mechanism to route knowledge correctly to expert agents. No accuracy, confusion matrix, ablation study, or evaluation of this inference step is provided, leaving the load-bearing conditioning mechanism unsupported and any attribution of gains to the proposed design unverified.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for the constructive feedback. The comments correctly identify areas where additional detail would strengthen the manuscript. We respond to each major comment below.

read point-by-point responses

  1. Referee: [Abstract] Abstract: the claim of consistent outperformance on realistic benchmarks is asserted without any reported metrics, baselines, controls, or experimental details, preventing assessment of whether results support the central claim that gains arise from mechanism-conditioned flow rather than the multi-agent setup alone.

    Authors: We agree that the abstract would benefit from quantitative support. In the revision we will add the primary performance metrics (e.g., average AUROC or F1 improvement) and list the main baseline categories to make the experimental claims more concrete. revision: yes

  2. Referee: [Planner agent / mechanism inference (method section)] Planner agent description: the architecture's performance edge requires reliable inference of the interaction mechanism to route knowledge correctly to expert agents. No accuracy, confusion matrix, ablation study, or evaluation of this inference step is provided, leaving the load-bearing conditioning mechanism unsupported and any attribution of gains to the proposed design unverified.

    Authors: We acknowledge that an explicit evaluation of the planner's mechanism inference is required to substantiate the conditioning mechanism. We will add an analysis of planner accuracy, a confusion matrix over mechanism classes, and an ablation that compares the full mechanism-conditioned system against a non-conditioned multi-agent variant. revision: yes

Circularity Check

0 steps flagged

No circularity: framework is a descriptive orchestration without self-referential reductions

full rationale

The paper presents DDIAgents as a multi-agent system where a planner infers mechanisms to route knowledge to expert agents. No equations, fitted parameters renamed as predictions, or derivation chains appear in the provided text. Claims rest on experimental outperformance against baselines rather than any internal reduction to inputs by construction. No self-citations are invoked as load-bearing uniqueness theorems, and the architecture is presented as an organizational proposal rather than a tautological redefinition of its own components. This is a standard non-circular empirical systems paper.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

Abstract provides no information on free parameters, axioms, or invented entities.

pith-pipeline@v0.9.1-grok · 5684 in / 1050 out tokens · 32936 ms · 2026-07-01T06:03:58.102471+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

56 extracted references · 7 canonical work pages · 4 internal anchors

  1. [1]

    Tassallah Abdullahi et al. 2025. K-paths: reasoning over graph paths for drug repurposing and drug interaction prediction. arXiv preprint arXiv:2502.13344 (2025)

    work page arXiv 2025

  2. [2]

    Josh Achiam, Steven Adler, Sandhini Agarwal, Lama Ahmad, Ilge Akkaya, Floren- cia Leoni Aleman, Diogo Almeida, Janko Altenschmidt, Sam Altman, Shyamal Anadkat, et al. 2023. GPT-4 technical report. arXiv preprint arXiv:2303.08774 (2023)

    work page internal anchor Pith review Pith/arXiv arXiv 2023

  3. [3]

    Daniil A Boiko, Robert MacKnight, Ben Kline, and Gabe Gomes. 2023. Au- tonomous chemical research with large language models. Nature 624, 7992 (2023), 570–578

    2023

  4. [4]

    Weize Chen, Yusheng Su, Jingwei Zuo, Cheng Yang, Chenfei Yuan, Chi-Min Chan, Heyang Yu, Yaxi Lu, Yi-Hsin Hung, Chen Qian, et al. 2023. Agentverse: facilitating multi-agent collaboration and exploring emergent behaviors. In International Conference on Learning Representations

    2023

  5. [5]

    Joseph A DiMasi, Henry G Grabowski, and Ronald W Hansen. 2016. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics 47 (2016), 20–33

    2016

  6. [6]

    Yilun Du, Shuang Li, Antonio Torralba, Joshua B Tenenbaum, and Igor Mordatch

  7. [7]

    In International Conference on Machine Learning

    Improving factuality and reasoning in language models through multiagent debate. In International Conference on Machine Learning

  8. [8]

    Zhengxiao Du, Yujie Qian, Xiao Liu, Ming Ding, Jiezhong Qiu, Zhilin Yang, and Jie Tang. 2022. GLM: general language model pretraining with autoregressive blank infilling. In Association for Computational Linguistics. 320–335

    2022

  9. [9]

    Abhimanyu Dubey, Abhinav Jauhri, Abhinav Pandey, Abhishek Kadian, Ahmad Al-Dahle, Aiesha Letman, Akhil Mathur, Alan Schelten, Amy Yang, Angela Fan, et al. 2024. The Llama 3 herd of models. arXiv preprint arXiv:2407.21783 (2024)

    work page internal anchor Pith review Pith/arXiv arXiv 2024

  10. [10]

    Alireza Ghafarollahi and Markus J Buehler. 2025. SciAgents: automating scientific discovery through bioinspired multi-agent intelligent graph reasoning.Advanced Materials 37, 22 (2025), 2413523

    2025

  11. [11]

    Zirui Guo, Lianghao Xia, Yanhua Yu, Tu Ao, and Chao Huang. 2024. LightRAG: simple and fast retrieval-augmented generation.arXiv preprint arXiv:2410.05779 (2024)

    work page internal anchor Pith review Pith/arXiv arXiv 2024

  12. [12]

    Ke Han, Peigang Cao, Yu Wang, Fang Xie, Jiaqi Ma, Mengyao Yu, Jianchun Wang, Yaoqun Xu, Yu Zhang, and Jie Wan. 2022. A review of approaches for predicting drug–drug interactions based on machine learning. Frontiers in Pharmacology 12 (2022), 814858

    2022

  13. [13]

    Sirui Hong, Mingchen Zhuge, Jonathan Chen, Xiawu Zheng, Yuheng Cheng, Jinlin Wang, Ceyao Zhang, Zili Wang, Steven Ka Shing Yau, Zijuan Lin, et al

  14. [14]

    In International Conference on Learning Representations

    MetaGPT: meta programming for a multi-agent collaborative framework. In International Conference on Learning Representations

  15. [15]

    Yubin Kim, Chanwoo Park, Hyewon Jeong, Yik S Chan, Xuhai Xu, Daniel Mc- Duff, Hyeonhoon Lee, Marzyeh Ghassemi, Cynthia Breazeal, and Hae W Park

  16. [16]

    Advances in Neural Information Processing Systems 37 (2024), 79410–79452

    MDagents: an adaptive collaboration of LLMs for medical decision-making. Advances in Neural Information Processing Systems 37 (2024), 79410–79452

    2024

  17. [17]

    Xuan Lin, Lichang Dai, Yafang Zhou, Zu-Guo Yu, Wen Zhang, Jian-Yu Shi, Dong- Sheng Cao, Li Zeng, Haowen Chen, Bosheng Song, et al. 2023. Comprehensive evaluation of deep and graph learning on drug–drug interactions prediction. Briefings in Bioinformatics 24, 4 (2023), bbad235

    2023

  18. [18]

    Guangyi Liu, Yongqi Zhang, Xunyuan Liu, and Quanming Yao. 2025. Case-based reasoning enhances the predictive power of LLMs in drug-drug interaction.arXiv preprint arXiv:2505.23034 (2025)

    work page arXiv 2025

  19. [19]

    Zun Liu et al . 2022. Predict multi-type drug–drug interactions in cold start scenario. BMC Bioinformatics (2022), 75

    2022

  20. [20]

    José Macías-Barragán, Ana Sandoval-Rodríguez, Jose Navarro-Partida, and Juan Armendáriz-Borunda. 2010. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis & Tissue Repair 3, 1 (2010), 16

    2010

  21. [21]

    Jin Niu, Robert M Straubinger, and Donald E Mager. 2019. Pharmacodynamic drug–drug interactions. Clinical Pharmacology & Therapeutics 105, 6 (2019), 1395–1406

    2019

  22. [22]

    Arnold K Nyamabo, Hui Yu, and Jian-Yu Shi. 2021. SSI–DDI: substructure– substructure interactions for drug–drug interaction prediction. Briefings in Bioinformatics 22, 6 (2021), bbab133

    2021

  23. [23]

    Caterina Palleria, Antonello Di Paolo, Chiara Giofrè, Chiara Caglioti, Giacomo Leuzzi, Antonio Siniscalchi, Giovambattista De Sarro, and Luca Gallelli. 2013. Pharmacokinetic drug–drug interaction and their implication in clinical manage- ment. Journal of Research in Medical Sciences 18, 7 (2013), 601

    2013

  24. [24]

    Vinay Prasad, Kevin De Jesús, and Sham Mailankody. 2017. The high price of anticancer drugs: origins, implications, barriers, solutions. Nature Reviews Clinical Oncology 14, 6 (2017), 381–390

    2017

  25. [25]

    Yang Qiu, Yang Zhang, Yifan Deng, Shichao Liu, and Wen Zhang. 2021. A comprehensive review of computational methods for drug-drug interaction de- tection. IEEE/ACM Transactions on Computational Biology and Bioinformatics 19, 4 (2021), 1968–1985

    2021

  26. [26]

    Kithusshand Raveendran, Deshan Sumanathilaka, Kanagasabai Thiruthanigesan, Pavinithan Retnakumar, and Yathukulan Sivapiragasam. 2025. PharmaMap-LLM: Fine-Tuning Large Language Models for Drug-Drug Interaction (DDI) Analysis. In International Conference on Advancements in Computing (ICAC). 1–6

    2025

  27. [27]

    Arthur G Roberts and Morgan E Gibbs. 2018. Mechanisms and the clinical relevance of complex drug–drug interactions. Clinical Pharmacology: Advances and Applications (2018), 123–134. Conference’17, July 2017, Washington, DC, USA Zhenqian Shen, Yu Liu, Xiaoyi Fu, and Quanming Yao

    2018

  28. [28]

    David Rogers and Mathew Hahn. 2010. Extended-connectivity fingerprints. Journal of Chemical Information and Modeling 50 (2010), 742–754

    2010

  29. [29]

    Jae Yong Ryu et al. 2018. Deep learning improves prediction of drug–drug and drug–food interactions. Proceedings of the National Academy of Sciences 115 (2018), E4304–E4311

    2018

  30. [30]

    Leyang Shen, Gongwei Chen, Rui Shao, Weili Guan, and Liqiang Nie. 2024. MoME: mixture of multimodal experts for generalist multimodal large language models. Advances in Neural Information Processing Systems 37 (2024), 42048–42070

    2024

  31. [31]

    Freda Shi, Xinyun Chen, Kanishka Misra, Nathan Scales, David Dohan, Ed H Chi, Nathanael Schärli, and Denny Zhou. 2023. Large language models can be easily distracted by irrelevant context. In International Conference on Machine Learning. 31210–31227

    2023

  32. [32]

    Noah Shinn, Federico Cassano, Ashwin Gopinath, Karthik Narasimhan, and Shunyu Yao. 2023. Reflexion: language agents with verbal reinforcement learning. Advances in Neural Information Processing Systems 36 (2023), 8634–8652

    2023

  33. [33]

    Xiaorui Su et al. 2024. Dual-channel learning framework for drug-drug interac- tion prediction via relation-aware heterogeneous graph transformer. In AAAI Conference on Artificial Intelligence. 249–256

    2024

  34. [34]

    Kyle Swanson, Wesley Wu, Nash L Bulaong, John E Pak, and James Zou. 2025. The virtual lab of AI agents designs new SARS-CoV-2 nanobodies. Nature (2025), 1–3

    2025

  35. [35]

    Xiangru Tang, Anni Zou, Zhuosheng Zhang, Ziming Li, Yilun Zhao, Xingyao Zhang, Arman Cohan, and Mark Gerstein. 2024. Medagents: large language models as collaborators for zero-shot medical reasoning. In Findings of the Association for Computational Linguistics. 599–621

    2024

  36. [36]

    Nicholas P Tatonetti et al . 2012. Data-driven prediction of drug effects and interactions. Science Translational Medicine (2012)

    2012

  37. [37]

    Gemma Team, Morgane Riviere, Shreya Pathak, Pier Giuseppe Sessa, Cassidy Hardin, Surya Bhupatiraju, Léonard Hussenot, Thomas Mesnard, Bobak Shahriari, Alexandre Ramé, et al. 2024. Gemma 2: improving open language models at a practical size. arXiv preprint arXiv:2408.00118 (2024)

    work page internal anchor Pith review Pith/arXiv arXiv 2024

  38. [38]

    Qwen Team. 2024. Qwen2.5: a party of foundation models. https://qwenlm. github.io/blog/qwen2.5/

    2024

  39. [39]

    Yaqing Wang, Zhenlin Luo, Peiyao Zhao, Yunfeng Cai, and Quanming Yao. 2026. Beyond scaling: A survey on data-efficient agentic learning. InInternational Joint Conference on Artificial Intelligence

    2026

  40. [40]

    Kwok, and Lionel M

    Yaqing Wang, Quanming Yao, James T. Kwok, and Lionel M. Ni. 2020. Generalizing from a few examples: A survey on few-shot learning. Comput. Surveys 53, 3, Article 63 (2020), 34 pages. https://doi.org/10.1145/3386252

    work page doi:10.1145/3386252 2020

  41. [41]

    Rick A Weideman, Ira H Bernstein, and W Paul McKinney. 1999. Pharmacist recognition of potential drug interactions. American Journal of Health-System Pharmacy 56, 15 (1999), 1524–1529

    1999

  42. [42]

    David S Wishart et al . 2018. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research 46 (2018), 1074–1082

    2018

  43. [43]

    Lingxuan Xie, Tengfei Ma, Yuqin He, Yiping Liu, and Xiangxiang Zeng. 2025. Predicting Drug–Drug Interaction via Dual-Drug Visual Representation. Journal of Chemical Information and Modeling 65, 19 (2025), 9999–10010

    2025

  44. [44]

    Chengqi Xu et al. 2024. DDI-GPT: explainable prediction of drug-drug interac- tions using large language models enhanced with knowledge graphs. bioRxiv (2024), 2024–12

    2024

  45. [45]

    Ziduo Yang, Weihe Zhong, Qiujie Lv, and Calvin Yu-Chian Chen. 2022. Learning size-adaptive molecular substructures for explainable drug–drug interaction prediction by substructure-aware graph neural network. Chemical Science 13, 29 (2022), 8693–8703

    2022

  46. [46]

    Junfeng Yao et al . 2022. Effective knowledge graph embeddings based on multidirectional semantics relations for polypharmacy side effects prediction. Bioinformatics 38 (2022), 2315–2322

    2022

  47. [47]

    Jingjing Yu, Ichiko D Petrie, René H Levy, and Isabelle Ragueneau-Majlessi

  48. [48]

    Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the US Food and Drug Administration in

  49. [49]

    Drug Metabolism and Disposition 47, 2 (2019), 135–144

    2019

  50. [50]

    Yue Yu et al. 2021. SumGNN: multi-typed drug interaction prediction via efficient knowledge graph summarization. Bioinformatics 37 (2021), 2988–2995

    2021

  51. [51]

    Yongqi Zhang et al. 2023. Emerging drug interaction prediction enabled by a flow- based graph neural network with biomedical network. Nature Computational Science 3 (2023), 1023–1033

    2023

  52. [52]

    Fangqi Zhu et al . 2023. Learning to describe for predicting zero-shot drug- drug interactions. In Conference on Empirical Methods in Natural Language Processing

    2023

  53. [53]

    Case-Based Reasoning

    Marinka Zitnik et al . 2018. Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics 34 (2018), 457–466. DDIAgents: Mechanism-Conditioned Context Flow for Drug-Drug Interaction Prediction Conference’17, July 2017, Washington, DC, USA A Supplementary Information A.1 Description of DDI Examples in Motivation Part In Table 6, we ...

    2018

  54. [54]

    Carefully read the drug-drug interaction prediction problem with candidate choices and feedbacks from last iteration round

  55. [55]

    Based on the problem, provide three experts that are suitable to answer the question from different perspectives

  56. [56]

    Cardiologist

    Provide three expert names and use one sentence to describe their roles, respectively. You should output in exactly the same format as: (1) [expert1 name]: [one sentence describes the role of expert1]. (2) [expert2 name]: [one sentence describes the role of expert2]. (3) [expert3 name]: [one sentence describes the role of expert3]. Question: {{Question}} ...

    2017